Epilepsy
Conditions
Interventions
TPM Group:The initial dosage for adolescents and adults was 25 milligram twice per day, with a weekly escalation of 25 milligram per day.
VPA Group :The starting dosage of VPA for adolescents and adults was 400 mg/d, with a weekly escalation of 100mg/d until the target dosage (800-1800 mg/d) was reached. The maximum dosage was 2000 mg/d
Sponsors
Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male and female aged 18 to 70 years old; 2. Patients who were definitively diagnosed with partial or generalised epilepsy. The seizure types and the types of epilepsy were defined according to the guidelines of 1981 and 1989 by the International League Against Epilepsy (ILAE); 3. Newly diagnosed epileptic patients who never received AED(s); 4. Patients who can count the number of seizure onsets; 5. The female under the child-bearing periods who used the admitted contraceptive methods; 6. Patients with clear consciousness, voluntary participation and agreed to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with progressive central neurological diseases; 2. Patients with pseudo-seizures or patients with acute sympomatic seizures; 3. Patients with contraindication of topiramate of valproate; 4. The pregnant and lactating patients; 5. Patients with sever mental retardation; 6. Patients with history of psychiatric problems; 7 Patients with clinically significant organic diseases before treatment, such as cardiovascular system problems, abnormal liver function, abnormal kidney function, abnormal haematological system function; 8. Patients with maligant tumor; 9. Patients with urinary calculus; 10. Patients who were definitively diagnosed with epilepsy syndromes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time from randomisation to treatment failure;Time from randomisation to the achievement of a 12-month remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| The total incidence of clinically importment adverse effects;Time from randomisation to a first seizure;The total incidence of clinically importment adverse;The incidence of severe adverse effect; | — |
Countries
China
Contacts
Public ContactXuefeng Wang
Outcome results
None listed